Apogee Therapeutics (APGE) CFO sells 2,000 shares in Rule 10b5-1 trades

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, she sold 792 shares of common stock at a weighted average price of $65.21, 1,108 shares at $66.15, and 100 shares at $66.89.

The weighted average prices reflect multiple trades in ranges from $64.80 to $65.61 and from $65.84 to $66.75. After these transactions, she directly owned 183,371 shares of Apogee common stock.

Insider Trade Summary

Net Seller: 2,000 shares ($131,630)

Net Sell 3 txns

Insider Henderson Jane

Role Chief Financial Officer

Sold 2,000 shs ($132K)

Type	Security	Shares	Price	Value
Sale	Common Stock	792	$65.21	$52K
Sale	Common Stock	1,108	$66.15	$73K
Sale	Common Stock	100	$66.89	$7K

Holdings After Transaction: Common Stock — 184,579 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.84 to $66.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

02/04/2026 - 08:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last)

(First)

(Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/02/2026		S⁽¹⁾		792	D	$65.21⁽²⁾	184,579	D
Common Stock	02/02/2026		S⁽¹⁾		1,108	D	$66.15⁽³⁾	183,471	D
Common Stock	02/02/2026		S⁽¹⁾		100	D	$66.89	183,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.84 to $66.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apogee Therapeutics (APGE) report?

Apogee Therapeutics reported stock sales by its Chief Financial Officer, Jane Henderson. On February 2, 2026, she sold three blocks of common stock totaling 2,000 shares, with trades reported at weighted average prices between $65.21 and $66.89 per share.

How many Apogee (APGE) shares did the CFO sell and at what prices?

Jane Henderson sold 792 Apogee shares at $65.21, 1,108 shares at $66.15, and 100 shares at $66.89. Some prices are weighted averages for multiple trades within narrow ranges around those reported per-share amounts.

How many Apogee Therapeutics (APGE) shares does the CFO still own?

After the reported transactions, Chief Financial Officer Jane Henderson directly owned 183,371 shares of Apogee Therapeutics common stock. This figure reflects her holdings following the sale of a combined 2,000 shares on February 2, 2026.

Were the Apogee (APGE) CFO’s stock sales under a trading plan?

Yes. The filing states the February 2, 2026 stock sales were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025, providing a pre-arranged schedule for selling shares independent of day-to-day market decisions.

What are the price ranges for the Apogee (APGE) insider sales?

The weighted average price of $65.21 reflects sales between $64.80 and $65.61 per share, while the $66.15 weighted average reflects sales between $65.84 and $66.75. The CFO agreed to provide full breakdowns of shares sold at each price upon request.

Who is the insider involved in this Apogee Therapeutics (APGE) Form 4?

The insider is Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. She is listed as an officer but not a director or 10% owner, and the reported transactions involve her directly held common stock in the company.